Next 10 |
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-05-28 06:10:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks. Developing therapeutics to cure diseases ...
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that ...
A look at the top 10 most actives in the United States Chicken Soup for the Soul Entertainment Inc. (CSSE) rose 179.3% to $0.4253 on volume of 213,352,319 shares Tesla Inc. (TSLA) rose 12.1% to $162.13 on volume of 179,967,315 shares PROSHARES TRUST (SQQQ) fell 0.8% to $11.81 on volume of...
Pegasystems Inc. (PEGA) is expected to report $0.2 for Q1 2024 Masco Corporation (MAS) is expected to report $0.87 for Q1 2024 Avery Dennison Corporation (AVY) is expected to report $2.15 for Q1 2024 Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A...
Genenta Science S.p.A. (GNTA) is expected to report for Q4 2023
Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company engaged in the development of a proprietary hematopoietic stem cell therapy for the treatment of a variety of solid tumor cancers. Temferon(TM) is based on ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/prog...
MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced th...
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harn...
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the...
News, Short Squeeze, Breakout and More Instantly...
Genenta Science S.p.A. Company Name:
GNTA Stock Symbol:
NASDAQ Market:
Genenta Science S.p.A. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that ...